KED Global reported that Celltrion Inc. will provide biosimilars worth ₩423.6B (US$323M) to its global sales and marketing affiliate Celltrion Healthcare Co., Celltrion’s largest supply deal. The supplies include Yuflyma® (adalimumab, biosimilar to AbbVie’s Humira®), Remsima® and Remsima SC® (infliximab “biobetter” to Janssen’s Remicade®), Truxima® (rituximab, biosimilar to Genentech/Biogen’s Rituxan®) Herzuma® (trastuzumab, biosimilar to Genentech’s Herceptin®), and Vegzelma® (bevacizumab, biosimilar to Genentech’s Avastin®).
On 18 September 2023, Celltrion won bids to supply Yuflyma® in five regions of Italy, and On 11 May 2023, Celltrion won bids to supply Vegzelma® (bevacizumab) in Italy and Belgium.